secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2026-05-12T20:10:17+00:00
Accession:  0001193125-26-219421
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Q1 2026 net loss $4.8M; cash $53.4M; new COR1 program launched
----------------------------------------------------------------------

- Net loss $4.8M ($0.02 basic/$0.03 diluted EPS) vs $4.1M loss in Q1 2025.
- Revenue $1.7M (+$0.2M YoY) driven by new WDI collaboration.
- Cash & marketable securities $53.4M; expected to fund ops into Q2 2028.
- Launched COR1 corneal endothelial cell therapy; second OPC1 spinal cord patient dosed.
- First AlloSCOPE 5D milestone achieved; Joachim Fruebis appointed founding SAB member.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000119312526219421/0001193125-26-219421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000119312526219421/lctx-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer